This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor (TPr) antagonist, on stroke incidence in spontaneously hypertensive stroke-prone rats (SHRSP). The effects of terutroban were compared to those of aspirin, an another anti-platelet agent, and rosuvastatin, known to exert end-organ protection in SHRSP.
Introduction
Several clinical and experimental studies (Widlansky et al., 2003; Huang and Vita, 2006) support the hypothesis that endothelial dysfunction and systemic inflammation play key roles in the pathogenesis of vascular diseases, including myocardial and brain ischemia. Human studies have demonstrated positive association between systemic inflammation induced by endotoxin infusion and marked endothelial dysfunction as well as impaired responses to vasoactive compounds (Pleiner et al., 2004 ). An analysis of the Framingham Heart Study Offspring cohort found that serum CRP, IL-6 and sICAM-1 levels inversely correlated with brachial artery flow-mediated dilation and reactive hyperemia in the forearm, although this relationship was weakened after adjusting for traditional risk factors (Vita et al., 2004) .
Spontaneously hypertensive stroke-prone rats (SHRSP) develop hypertension and proteinuria and die after the onset of cerebrovascular damage, which is invariably preceded by systemic inflammation and endothelial dysfunction (Sironi et al., 2001; Ballerio et al., 2007) . Notably, systemic inflammation is characterized by an accumulation -in serum and urine -of acutephase high molecular weight (HMW) proteins such as thiostatin, the most common marker of inflammation in rat (Sironi et al., 2001) . In SHRSP, brain lesions have a vasogenic origin due to the blood-brain barrier impairment (Guerrini et al., 2002) . Therefore, this model is particularly suited to reveal cerebrovascular benefits of drugs acting on the inflammatory cascade and/or endothelial dysfunction.
The purpose of this study was to evaluate in SHRSP the effects of terutroban, a highly selective and long-acting TP receptor (TPr) antagonist with antithrombotic, antivasoconstrictive and anti-inflammatory/antiatherosclerotic properties (Cimetière et al., 1998) . Previous experimental studies have demonstrated that terutroban prevents vascular wall proliferation and atherogenesis (Cheng et al., 2002; Worth et al., 2005; Viles-Gonzalez et al., 2005) , increases anti-oxidant enzymes like glutathione peroxidase (Sebekova et al., JPET#165787 5 2007) and has anti-inflammatory actions in vitro and in vivo (decreased macrophage infiltration and ICAM-1) (Cayatte et al., 2000) . Terutroban also improved endothelial function in patients with coronary artery disease treated with aspirin (Belhassen et al., 2003) .
Terutroban is developed in secondary prevention of cerebrovascular and cardiovascular events in patients with an history of ischemic stroke or transient ischemic attack (Bousser et al., 2009a and 2009b) .
In this study, the optimally effective dose of terutroban established in previous works was compared to those of aspirin (ASA) and rosuvastatin (RSV) to provide comparative data on end-organ protection and anti-inflammation in SHRSP (Sironi et al., 2005) .
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The rats were anesthetised with 1.5% isofluorane (Merial, Toulose, France) 
O 2 , and placed inside a Bruker AvanceII 4.7T with a micro-imaging accessory. After a scout image, sixteen contiguous 1 mm thick slices were analyzed caudally to the olfactory bulb using a field of view (FOV) of 4 x 4 cm 2 , and a turbo spin echo sequence with 16 echoes per excitation, 10 ms inter-echo time, 85 ms equivalent echo time, and 4 s repetition time. Eight T2-weighted images of 128 x 128 pixels (zero-filled to 256x256) were averaged in 8'30". The occurrence of lesions was defined as the presence of areas of high signal intensity on T2-weighted images.
Proteinuria studies
One-dimensional electrophoresis (1-DE) of urine proteins (50 μg) was run in the presence of SDS without sample reduction in a discontinuous buffer system on 4-12% polyacrylamide gels stained with Colloidal Blue. Densitometry was performed using Quantity One version 4.5.2 (Biorad, Hercules, CA) to evaluate the percentage of low molecular weight (LMW) and high molecular weight (HMW) proteins density.
to evaluate the expression of IL-1beta, TGF-beta, and MCP-1. All the reagents used were purchased from Invitrogen (Carlsbad, CA)
Expression of eNOS
eNOS expression was evaluated by RT-PCR on carotid artery homogenates from animals sacrificed after six weeks of treatment.
Endothelial dysfunction
Isolated carotid artery rings (3 mm) were suspended in an individual organ bath filled with Krebs solution and their vascular reactivity was evaluated as previously described (Ballerio et al., 2007) . Indomethacin (10 -5 mol/L; Chiesi Farmaceutici S.p.A., Parma) was added to Krebs solutions in order to inhibit prostanoid synthesis. Arteries were challenged with KCl (100 mM/L) to check the viability of tissues; vessels not responding to KCl were discarded. 
Statistics
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Results

Physiological parameters and survival of SHRSP
Body weight increased similarly in all experimental groups. The severe hypertension that developed was not affected by any of the drug treatments (Fig. 1A) . Plasma total cholesterol and triglyceride levels (42.38±3.89 and 68.5±8.96 mg/dl respectively at baseline), did not significantly change during the treatment period in any groups. Vehicle-treated animals developed cerebral lesions 42.4±10.8 days after starting salt loading. All treatments significantly delayed the appearance of cerebrovascular damages ( Fig. 1B and 1D ). However, the delay of occurrence observed under terutroban (87.6±19.2 days; p<0.001) was greater than that induced by aspirin (63.9±9.01 days; p<0.05) and comparable to that observed after RSV (85.6±16.9 days; p<0.001). Comparison of survival clearly shows the effectiveness of all treatments ( Fig.1C ). Compared to the vehicle group, survival was similarly increased by terutroban and RSV (p<0.001) and this effect was significantly superior to that observed after aspirin treatment (RSV p<0.05; terutroban p< 0.01).
Serum TXB 2 and urinary 11-dehydro-TXB 2 levels
As expected, serum TXB 2 and urinary 11-dehydro-TXB 2 levels were significantly decreased by ASA while the levels were not affected by salt loading, nor by RSV or terutroban treatment ( Fig. 2A and 2B ).
Proteinuria and composition of urinary proteins
The SHRSP receiving vehicle developed progressively a severe proteinuria. After 4.7±1.3
weeks of salt loading, proteinuria was higher than 100 mg/day and increased rapidly and linearly to reach an average of 266±28.9 mg/day after 7 weeks. Treatment with terutroban and RSV delayed significantly the increase in proteinuria (10.5±3.4 weeks, p<0.001, and 9.1±1.9
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3 ), the most abundant excreted protein was the major urinary protein (MUP or alpha-2u-globulin) which represents the major protein excreted in urine of healthy male rats (Sironi et al., 2001) .MUP, together with other LMW proteins, accounted for about 70% of the total protein content. Protein composition changed over time in the salt-loaded SHRSP, with an accumulation of HMW proteins previously identified as markers of inflammation (Ballerio et al., 2007) , and a simultaneous decrease in LMW proteins (Fig. 3A) . In the vehicle group, HMW proteins reached 70% of the total protein content 4-5 weeks after the start of dietary treatment (Fig. 3A) ; in the ASA-and RSV-treated rats, HMW proteins became preponderant after seven and nine weeks respectively ( Fig. 3B and 3C ). Densitometric analysis of the excreted proteins in the terutroban group showed that the HMW proteins level did not increase to more than 50% of total protein content even after 14-15 weeks of treatment (Fig.   3D ).
Brain expression of inflammatory markers
In comparison with vehicle-treated animals, all the drugs markedly reduced the accumulation of IL-1beta, MCP-1 and TGF-beta mRNA in the brain tissues (Fig. 4) .
Endothelial dysfunction
The response curves to phenylephrine in carotid artery rings showed significantly reduced contraction in terutroban-treated rats (p<0.05). ASA and RSV treatment also tended to reduce the contractions caused by phenylephrine (n.s.) (Fig. 5A ). In rings pre-contracted with phenylephrine, the concentration-response curves to the administration of the NO donor sodium nitroprusside were comparable in all groups ( relaxation evoked by acetylcholine was not altered by ASA, but was significantly increased by terutroban and RSV (p<0.01) (Fig. 5C ). Incubation with L-NAME abolished the acetylcholine-induced relaxation in all experimental groups (Fig. 5C ). There was no difference in sensitivity (pD 2 ) among the experimental groups whatever the experimental condition (Tab. 1).
Carotid eNOS expression
Terutroban and rosuvastatin increased the expression of eNOS mRNA (1.98±0.66, p<0.05 and 1.85±0.40, n.s. vs 1.04±0.37 AU in vehicle group respectively), while aspirin did not have any effect (1.31±0.6 AU).
Discussion
In this study, we investigated the effects of terutroban, a TP receptor antagonist, on the pathological events that spontaneously develop in SHRSP. The effects induced by terutroban were compared with those of aspirin, a cyclo-oxygenase inhibitor, and rosuvastatin, a statin which demonstrated beneficial effects in this model (Sironi et al., 2005) .
In salt-loaded SHRSP, terutroban delayed the occurrence of spontaneous brain lesions and consequently increased the survival, regardless of any effect on blood pressure or on serum TXB 2 levels. Terutroban was more effective in brain damage protection than aspirin, and had similar effects as rosuvastatin. In a previous study, a beneficial effect was also observed when terutroban was administered three weeks after the start of dietary treatment, thus indicating that terutroban can also reverse ongoing pathological events in salt-loaded SHRSP (Gelosa et al., 2007) .
Mechanisms that could contribute to the beneficial effect of TP receptor blockade on stroke prevention in this model, are an attenuation of the systemic inflammation that invariably prostacyclin), which is impaired by COX inhibition and (2) inhibiting the production of vasoconstrictor prostanoids other than TXA 2 (Cayatte et al., 2000) . Moreover, the improvement of endothelium-dependent relaxation was inhibited after incubation with L-NAME, suggesting a partial restoration of NO release or synthesis by terutroban. This hypothesis is strengthened by the increased expression of eNOS mRNA in the carotid arteries of animals treated with terutroban, whereas expression of eNOS mRNA was not changed Benefits on survival induced by terutroban were independent of modifications in TXB 2 levels, which remained unchanged after terutroban administration, contrary to aspirin, which almost suppressed the production of TXA 2 (as reflected by a reduction of its serum metabolite TXB 2 ) but with an effect on survival that was significantly inferior to that obtained with terutroban.
The greater effect of TPr antagonism with terutroban on brain protection could be attributed to a greater effect in inflammation processes at systemic level, and is probably due to ligands other than TXA 2 and prostaglandins-endoperoxides (PGG 2 and PGH 2 ). It was beyond the scope of our study to identify the eicosanoids potentially responsible for activating the inflammatory cascade involved in end-organ damage in SHRSP, but possible candidates are the isoprostanes, produced from arachidonic acid by non enzymatic oxidation, and whose formation is not influenced by COX inhibitors. This hypothesis is corroborated by the results obtained by Ishizuka et al. (Ishizuka et al., 2007) who suggested that cerebrovascular inflammation in salt-loaded SHRSP may be due to TP receptor stimulation by 8-iso-PGF 2α .
In this study, the effect of terutroban was similar to that of rosuvastatin, an effective drug in preventing end-organ damage in a model of SHRSP (Sironi et al., 2005) . Terutroban increased survival to a greater extent than aspirin, probably due to its greater effects on systemic inflammation and endothelial dysfunction.
The benefits of terutroban on survival and pathological events occurring in SHRSP may therefore be attributed to its anti-inflammatory activity, along with the improvement of endothelial function. 
